86
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals

, , , , &
Pages 495-503 | Published online: 16 Aug 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Eva Lesén, Åse Björstad, Ingela Björholt, Tom Marlow, Entela Bollano, Marion Feuilly, Florence Marteau, Staffan Welin, Anna-Karin Elf & Viktor Johanson. (2018) Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study. Scandinavian Journal of Gastroenterology 53:12, pages 1509-1518.
Read now

Articles from other publishers (8)

Cesar L. Boguszewski, Márta Korbonits, Audrey Artignan, Almudena Martín García, Aude Houchard, Antonio Ribeiro-OliveiraJrJr & Wouter W. de Herder. (2022) Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review. Endocrine 79:3, pages 527-536.
Crossref
Yue Ma, Yuxin Li, Aixia Ma & Hongchao Li. (2021) Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study. Frontiers in Public Health 9.
Crossref
B. E. White, R. Mujica-Mota, T. Snowsill, E. M. Gamper, R. Srirajaskanthan & J. K. Ramage. (2020) Evaluating cost-effectiveness in the management of neuroendocrine neoplasms. Reviews in Endocrine and Metabolic Disorders 22:3, pages 647-663.
Crossref
Andrew J. Klink, Bruce Feinberg, Hsing-Ting Yu, David Ray, Sonia Pulgar, Alexandria Phan & Aaron Vinik. (2019) Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors. The Oncologist 24:10, pages 1331-1339.
Crossref
P Ryan, A McBride, D Ray, S Pulgar, RA Ramirez, E Elquza, JP Favaro & G Dranitsaris. (2019) Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis. Journal of Oncology Pharmacy Practice 25:6, pages 1425-1433.
Crossref
Enrique Grande, Ángel Díaz, Carlos López, Javier Munarriz, Juan-José Reina, Ruth Vera, Beatriz Bernárdez, Javier Aller, Jaume Capdevila, Rocio Garcia-Carbonero, Paula Jimenez Fonseca & Marta Trapero-Bertran. (2019) Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review. Therapeutic Advances in Endocrinology and Metabolism 10, pages 204201881982821.
Crossref
Monika Wagner, Dima Samaha, Hanane Khoury, William M. O’Neil, Louis Lavoie, Liga Bennetts, Danielle Badgley, Sylvie Gabriel, Anthony Berthon, James Dolan, Matthew H. Kulke & Mireille Goetghebeur. (2017) Development of a Framework Based on Reflective MCDA to Support Patient–Clinician Shared Decision-Making: The Case of the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the United States. Advances in Therapy 35:1, pages 81-99.
Crossref
. (2017) Lanreotide reduces hospital costs for metastatic GEP-NETs. PharmacoEconomics & Outcomes News 785:1, pages 21-21.
Crossref